Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Clarus Therapeutics Hldgs Inc WT (CRXTW)

Clarus Therapeutics Hldgs Inc WT (CRXTW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Clarus Therapeutics Announces Notice of Allowance for Additional Patent Claims Covering JATENZO® (testosterone undecanoate) Globe Newswire - Thu Jul 28, 2022

JATENZO is the first and only FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain...

CRXT : 0.0475 (-31.16%)
CRXTW : 0.0101 (-26.28%)
Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at ENDO 2022, the Endocrine Society’s Annual Meeting Globe Newswire - Thu Jun 9, 2022

JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical...

CRXT : 0.0475 (-31.16%)
CRXTW : 0.0101 (-26.28%)
Clarus Therapeutics Announces Issuance of Patent Covering JATENZO® (testosterone undecanoate) Globe Newswire - Wed May 18, 2022

JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical...

CRXT : 0.0475 (-31.16%)
CRXTW : 0.0101 (-26.28%)
Clarus Therapeutics Reports First Quarter 2022 Financial and Operating Results Globe Newswire - Mon May 16, 2022

First quarter 2022 net revenue increased 72% year-over-year to $4.0 million First quarter 2022 total prescription growth for JATENZO® increased 12%...

CRXT : 0.0475 (-31.16%)
CRXTW : 0.0101 (-26.28%)
Clarus Therapeutics to Report First Quarter 2022 Financial and Operating Results Globe Newswire - Thu May 12, 2022

NORTHBROOK, Ill., May 12, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to...

CRXTW : 0.0101 (-26.28%)
CRXT : 0.0475 (-31.16%)
Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering CLAR-121 (Testosterone + Anastrozole) for Treatment of Androgen-Mediated Autoimmune Inflammatory Mastitis Globe Newswire - Tue May 10, 2022

Initial focus for CLAR-121 is the treatment of periductal mastitis (PDM) in women Clarus is seeking Orphan Drug Designation from the U.S. Food and Drug...

CRXT : 0.0475 (-31.16%)
CRXTW : 0.0101 (-26.28%)
Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at the 2022 American Urological Association Annual Meeting Globe Newswire - Mon May 9, 2022

JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical...

CRXT : 0.0475 (-31.16%)
CRXTW : 0.0101 (-26.28%)
Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering JATENZO® (testosterone undecanoate) Globe Newswire - Thu Apr 28, 2022

JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical...

CRXT : 0.0475 (-31.16%)
CRXTW : 0.0101 (-26.28%)
Clarus Therapeutics Announces Closing of Upsized $30.0 Million Underwritten Public Offering Globe Newswire - Wed Apr 27, 2022

NORTHBROOK, Ill., April 27, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to...

CRXTW : 0.0101 (-26.28%)
CRXT : 0.0475 (-31.16%)
Clarus Therapeutics Announces Pricing of Upsized $30.0 Million Underwritten Public Offering Globe Newswire - Mon Apr 25, 2022

NORTHBROOK, Ill., April 25, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to...

CRXTW : 0.0101 (-26.28%)
CRXT : 0.0475 (-31.16%)

Barchart Exclusives

2 Vaccine Stocks to Buy on the Dip Barchart - 6 minutes ago
Given the cutting-edge pipeline for these two vaccine companies, double-digit slumps in these stocks present a compelling entry point for investors. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot